Many Moorpark adults face cataracts and glaucoma in the same decade. An early-phase trial presented at AAO 2026 tested whether an experimental intraocular lens that slowly releases bimatoprost can control eye pressure after cataract surgery without daily glaucoma drops.
Trial design in brief
Jeffrey Kammer, MD, of Vanderbilt University Medical Center and colleagues enrolled 106 people with glaucoma or ocular hypertension who were already scheduled for cataract surgery. About three-quarters received the drug-eluting lens at a low or high bimatoprost dose. The remaining quarter received a standard lens plus twice-daily timolol drops.
Twelve-month pressure results
- Mean pressure was about 15.9 mm Hg in the higher-dose lens group, 14.8 mm Hg in the lower-dose group, and 15.7 mm Hg in the standard-lens plus timolol group.
- More than 95% of patients with the drug-releasing lens needed no additional glaucoma medicine at one year.
- Patients will be followed for three years, and larger trials are underway.
Kammer noted that daily drops are hard to sustain and that combining cataract and glaucoma care in one operation is appealing. These are interim early-phase findings, not an FDA-approved product available in clinic today.
Why adherence makes this idea attractive
Missed glaucoma drops are one of the hardest problems in chronic eye care. A lens that releases medicine for months after cataract surgery could remove dozens of bottles from a patient’s year—if longer trials confirm safety, endothelial health, and lasting pressure control. Until then, standard lenses plus proven drops, lasers, or micro-invasive glaucoma options remain the evidence-based path most patients should expect.
How to read early device news
- Ask whether a technology is approved, investigational, or only presented as meeting data.
- Pressure control still needs optic-nerve and field monitoring even if drops stop.
- Not every glaucoma patient is having cataract surgery, so drop-free options will never cover everyone.
Khanna Vision Institute discusses proven cataract and glaucoma pathways first. Experimental lenses belong in research centers until regulators finish review. For neutral retina education while you follow systemic eye news, see piineye.com.
Source: Experimental cataract lens can treat glaucoma through time-release drugs (Medical Xpress (AAO 2026 / Vanderbilt report), 10/13/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.